Mesenchymal stromal cell function is not affected by drugs used in the treatment of inflammatory bowel disease

Cytotherapy

Volumn 13, Issue 9, 2011, Pages 1066-1073

  Duijvestein, Marjolijn ^a   Molendijk, Ilse ^a   Roelofs, Helene ^a   Vos, Anne Christine W ^a   Verhaar, Auke P ^a   Reinders, Marlies E J ^a   Fibbe, Willem E ^a   Verspaget, Hein W ^a   Van Den Brink, Gijs R ^a,b   Wildenberg, Manon E ^a   Hommes, Daniel W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

anti tumor necrosis factor ; Crohn's disease; immunomodulators; medication; mesenchymal stromal cell

Indexed keywords

5' NUCLEOTIDASE; AZATHIOPRINE; ENDOGLIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; THY 1 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADIPOCYTE; ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EXPOSURE; ENTERITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MESENCHYMAL STROMAL CELL; MESENCHYME CELL; OSTEOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; STROMA CELL;

EID: 80052875315     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.597379     Document Type: Article

References (36)

1. Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohns disease: results of a phase I study. Gut. 2010;59:1662-9.
2. Dominici M, Le BK, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defi ning multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-17. (Pubitemid 44269669)
3. Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohns fi stula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48:1416-23. (Pubitemid 40933870)
4. Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fi stula: a phase II clinical trial. Dis Colon Rectum. 2009;52:79-86.
5. Garcia-Olmo D, Herreros D, Pascual M, Pascual I, De-La-Quintana P, Trebol J, Garcia-Arranz M. Treatment of enterocutaneous fi stula in Crohns disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion. Int J Colorectal Dis. 2009;24:27-30.
6. Chen TG, Chen JZ, Wang XX. Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood. Cell Prolif. 2006;39:117-25.
7. Miriuka SG, Rao V, Peterson M, Tumiati L, Delgado DH, Mohan R, et al. mTOR inhibition induces endothelial progenitor cell death. Am J Transplant. 2006;6:2069-79. (Pubitemid 44199541)
8. Guo J, Zeng Y, Liang Y, Wang L, Su H, Wu W. Cyclosporine affects the proliferation and differentiation of neural stem cells in culture. Neuroreport. 2007;18:863-8. (Pubitemid 46791514)
9. Buhler L, Kurilla-Mahon B, Chang Q, Abraham S, Alwayn IP, Appel JZ, III, et al. Cryopreservation and mycophenolate therapy are detrimental to hematopoietic progenitor cells. Transplantation. 2002;74:1159-66. (Pubitemid 35216112)
10. Le BK, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579-86. (Pubitemid 351626841)
11. Ben-Horin S, Goldstein I, Fudim E, Picard O, Yerushalmi Z, Barshack I, et al. Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines. Gut. 2009;58: 396-403.
12. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-45. (Pubitemid 36519931)
13. Kurnik D, Loebstein R, Fishbein E, Almog S, Halkin H, Bar-Meir S, Chowers Y. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohns disease. Aliment Pharmacol Ther. 2003;18:57-63. (Pubitemid 36897981)
14. Moshkowitz M, Oren R, Tishler M, Konikoff FM, Graff E, Brill S, et al. The absorption of low-dose methotrexate in patients with infl ammatory bowel disease. Aliment Pharmacol Ther. 1997;11:569-73. (Pubitemid 27286960)
15. Bergan S, Rugstad HE, Bentdal O, Endresen L, Stokke O. Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. Ther Drug Monit. 1994;16:13-20. (Pubitemid 24042307)
16. Rutgeerts P, DH aens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Effi cacy and safety of retreatment with anti-tumor necrosis factor antibody (infl iximab) to maintain remission in Crohns disease. Gastroenterology. 1999; 117:761-9. (Pubitemid 29468216)
17. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, et al. Co-transplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem cell transplantation. Blood. 2007; 110:2764-7. (Pubitemid 47523204)
18. Bernardo ME, Ball LM, Cometa AM, Roelofs H, Zecca M, Avanzini MA, et al. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant. 2011;46:200-7.
19. Chan JL, Tang KC, Patel AP, Bonilla LM, Pierobon N, Ponzio NM, Rameshwar P. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood. 2006;107:4817-24. (Pubitemid 43882633)
20. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42-8. (Pubitemid 34059216)
21. Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and autoimmune disease patients reduce the proliferation of autologousand allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford). 2007;46:403-8. (Pubitemid 46344649)
22. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specifi c T cells to their cognate peptide. Blood. 2003;101:3722-9. (Pubitemid 36857965)
23. Wright DC, Deol HS, Tuch BE. A comparison of the sensitivity of pig and human peripheral blood mononuclear cells to the antiproliferative effects of traditional and newer immunosuppressive agents. Transpl Immunol. 1999;7:141-7.
24. Hornung N, Stengaard-Pedersen K, Ehrnrooth E, Ellingsen T, Poulsen JH. The effects of low-dose methotrexate on thymidylate synthetase activity in human peripheral blood mononuclear cells. Clin Exp Rheumatol. 2000;18:691-8.
25. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386-98. (Pubitemid 44464808)
26. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2:141-50. (Pubitemid 351181031)
27. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Infl amm Bowel Dis. 2007;13:1323-32. (Pubitemid 350206841)
28. Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, Buscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009;58:929-39.
29. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting infl ammatory and autoimmune responses. Gastroenterology. 2009;136:978-89.
30. Zhang Q, Shi S, Liu Y, Uyanne J, Shi Y, Shi S, Le AD. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate infl ammation-related tissue destruction in experimental colitis. J Immunol. 2009;183:7787-98.
31. Le Blanc K, Rasmusson I, Gotherstrom C, Seidel C, Sundberg B, Sundin M, et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol. 2004;60:307-15. (Pubitemid 39141263)
32. Maccario R, Moretta A, Cometa A, Montagna D, Comoli P, Locatelli F, et al. Human mesenchymal stem cells and cyclosporin a exert a synergistic suppressive effect on in vitro activation of alloantigen-specifi c cytotoxic lymphocytes. Biol Blood Marrow Transplant. 2005;11:1031-2. (Pubitemid 41754722)
33. Ringden O, Le Blanc K. Mesenchymal stem cells combined with cyclosporine inhibits cytotoxic T cells. Biol Blood Marrow Transplant. 2006;12:693-4.
34. Hoogduijn MJ, Crop MJ, Korevaar SS, Peeters AM, Eijken M, Maat LP, et al. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. Transplantation. 2008;86:1283-91.
35. Travis SP, Stange EF, Lemann M, Oresland T, Bemelman WA, Chowers Y, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008;2:24-62. (Pubitemid 351179488)
36. Dignass A, Van AG, Lindsay JO, Lemann M, Soderholm J, Colombel JF, et al. The second European evidence-based consensus on the diagnosis and management of Crohns disease: current management. J Crohns Colitis. 2010;4:28-62.